 | Up a level |
El-Khoueiry, Anthony B., Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk, Iqbal, Syma, Zhang, Xiaojing (Amily), Nakajima, Keiko and Galle, Peter R. (2020). Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 38 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
El-Khoueiry, Anthony B., Kim, Richard D., Harris, William Proctor, Sung, Max W., Waldschmidt, Dirk, Cabrera, Roniel, Garosi, Vittorio Luigi, Zebger-Gong, Hong, Brennan, Barbara J., Wang, Ying A., Mueller, Udo, Ishida, Tatiane Cristine and Galle, Peter R. (2021). Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk Thomas, Cabrera, Roniel, Mueller, Udo, Menezes, Flavia, Ishida, Tatiane, Galle, Peter R. and El-Khoueiry, Anthony B. (2021). Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755